Genenta Science SPA (Genenta Science SPA) Dividend Payout Ratio : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Genenta Science SPA Dividend Payout Ratio?

Genenta Science SPA's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Genenta Science SPA's Dividend Payout Ratio or its related term are showing as below:

GNTA's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.435
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-25), the Dividend Yield % of Genenta Science SPA is 0.00%.

Genenta Science SPA's Dividends per Share for the months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Genenta Science SPA Dividend Payout Ratio Historical Data

The historical data trend for Genenta Science SPA's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genenta Science SPA Dividend Payout Ratio Chart

Genenta Science SPA Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Genenta Science SPA Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Dividend Payout Ratio	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Genenta Science SPA's Dividend Payout Ratio

For the Biotechnology subindustry, Genenta Science SPA's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genenta Science SPA's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genenta Science SPA's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Genenta Science SPA's Dividend Payout Ratio falls into.

Genenta Science SPA Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Genenta Science SPA's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-0.685
	=	N/A

Genenta Science SPA's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.291
	=	N/A

Genenta Science SPA (NAS:GNTA) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Genenta Science SPA Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Genenta Science SPA's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Genenta Science SPA (Genenta Science SPA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genenta Science SPA (NAS:GNTA) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

K5F:Germany

Address

Via Olgettina No. 58, Milan, ITA, 20132

Website

https://www.genenta.com

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's lead product includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.